Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

BOULDER, Colo. and MONTREAL, Jan. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the enrollment of the first patient in a Phase 2 clinical trial (Trial CL002) evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Vidaza(R) (azacitidine for injection), Pharmion's DNA demethylating agent, in patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).

Patients will receive 75 mg/m2 of Vidaza either intravenously or subcutaneously in combination with an oral dose of MGCD0103 in 28 day cycles. Key objectives for this study are to determine the overall response rate, progression free survival and duration of response. The trial will enroll up to 75 patients at cancer centers in North America and will include a pharmacokinetic equivalency study.

"We are aggressively exploring the utility of epigenetic drug combinations in the treatment of cancer," said Andrew Allen, Pharmion's executive vice president and chief medical officer. "The biology of cancer suggests multiple epigenetic mechanisms cooperate to silence tumor suppressor genes, which raises the simple hypothesis that attacking these mechanisms with drug combinations may be superior to single-agent therapy. In this trial, we are combining Vidaza, our DNA methyltransferase inhibitor, with MGCD0103, our isotype-selective HDAC inhibitor, in a clinical study of this therapeutic approach. We are unique in our ability to conduct a trial like this, using drugs from our own portfolio."

"We are delighted to be participating in this trial of Vidaza and MGCD0103," commented Dr. Anas Younes, Professor of Medicine
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "North America Mammography Market ... 2019)"  report to their offering. ... is a detailed type of imaging that ... breasts. A mammography exam, called a mammogram, ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... third quarter 2011 financial results after the market closes on ... webcast will be held on Thursday, November 3, 2011, at ... To participate in the call, please dial 877-303-1298 (for U.S. ...
... 2011 IDenta Corp. (OTC: IDTA) CEO Yaacov Shoham today ... are succeeding in making sales in many new markets, including ... We have received an order for 2000 detectors from the ... In the past several months we have ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2
(Date:5/27/2015)... May 27, 2015 The BBB Code ... service practices that enhance customer trust and confidence in ... for Trust, eight principles that summarize important elements of ... represents standards for business accreditation by BBB. Businesses based ... standards and complete application procedures will be accredited by ...
(Date:5/27/2015)... 27, 2015 Hundreds of Risperdal ... of individuals who allegedly suffered gynecomastia (male breast ... of the antipsychotic drug continue to move forward ... Pennsylvania’s Philadelphia Court of Common Pleas. According to ... bellwether trial program, as the third trial involving ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 While hair ... hair loss, a new pilot study conducted by a ... Surgery (ISHRS) has found hair follicle grafting can help ... research was partially funded by ISHRS, which offers research ... to hair restoration. , In the past decade, ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Dr. Omar ... based in Stamford, CT has been selected as part ... first physicians nationwide (and the only physician in Connecticut) ... which allows for the removal of submental fat (double ... no recovery time, no surgery and minimal risks. Dr. ...
(Date:5/27/2015)... May 27, 2015 Black Book ... satisfaction surveys in the multiple services and software ... determine the highest ranked Electronic Health and Medical ... a special research focus on implemented EHR users, ... software vendors with the highest scores in client ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4
... LIONVILLE, Pa., Oct. 18 West Pharmaceutical,Services, Inc. ... to Pfizer,Inc.,s announcement that it has decided to ... marketing rights to the,Company,s customer, Nektar Therapeutics, Inc. ... that produce the Exubera inhalation device for Nektar. ...
... poorest prognosis -- those with a type of deadly tumor ... a drug that chokes off a tumors blood supply. ... Preston Robert Tisch Brain Tumor Center, a combination of bevacizumab ... agent, may increase the amount of time GBM patients can ...
... Patients Released From Hospital Within 24-48 Hours, ... Texas man is,the first brain tumor patient in ... that removes pituitary tumors without making incisions,in the ... and the,Director of the Trinity Mother Frances Neuroscience ...
... override SCHIP veto, WASHINGTON, Oct. 18 The ... a sad day when America,s children can,t depend on ... after their most basic needs. It,s,a sad day when ... citizens., "The failure of the House of Representatives ...
... students today said they were deeply saddened that Congress ... legislation to re-authorize the State Childrens Health Insurance Program ... another bill that provides comparable levels of funding and ... go far enough, said David C. Dale, MD, FACP, ...
... is a statement from Greg,Tarpinian, Executive Director of ... President Bush,s veto of SCHIP. "Change to ... and,some courageous Republicans to override President Bush,s veto ... whose parents cannot,afford it. "In failing to ...
Cached Medicine News:Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:Drug combination might offer hope for patients deadly brain tumors 2Health News:Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure 2Health News:Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure 3Health News:Congressional failure to override SCHIP veto 'saddens' physicians 2
... Mumps IgG ELISA test system is intended ... antibody in human serum. When performed according ... test, together with other clinical information, may ... and/or aid in the diagnosis of Mumps ...
... IgG Enzyme-linked Immunosorbent Assay (ELISA) is intended ... IgG antibody to Mumps virus in human ... for the determination of immune status. Paired ... to demonstrate seroconversion or a significant rise ...
... the TEG analyzer and the TEG analytical software, ... formation and dissolution of the clot, showing the ... TEG analyzer is the only hemostasis analyzer available ... proven model developed by Prof. Helmut Hartert in ...
... BareWire technology, the wire crosses the lesion ... catheter. All other actions, including filter placement ... then occur over the wire., ,Emboshield is ... off during a carotid stenting procedure, and ...
Medicine Products: